Page 5. We seem to be committed to partnership for Phase III. Something GK would have differed on.
Heavy emphasis on GDC-0084, no doubt as it is more advanced. Still not convinced re that strategy. Was it a friendly move by Genentech, in return for an early seat at the table for discussions on the other compounds?
Ann: Novogen Presents at Biotech Showcase Conference, page-6
Add to My Watchlist
What is My Watchlist?